Citation: Heart Failure Clinics. 15(1):65-75, 2019 Jan..Journal: Heart failure clinics.Published: ; 2019ISSN: 1551-7136.Full author list: Almuwaqqat Z; Meisel JL; Barac A; Parashar S.UI/PMID: 30449381.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Journal Article | ReviewOnline resources: Click here to access onlineDigital Object Identifier: https://dx.doi.org/10.1016/j.hfc.2018.08.007 (Click here)Abbreviated citation: Heart Fail Clin. 15(1):65-75, 2019 Jan.Abstract: Heart failure and breast cancer have shared risks and morbidities. Multimodality therapies for breast cancer, including conventional chemotherapy, targeted therapeutics, radiation therapy, and hormonal agents, may make patients more susceptible to asymptomatic left ventricular dysfunction and clinical heart failure during and after treatment. New or preexisting left ventricular dysfunction may lead to interruptions in cancer treatment and limit options of breast cancer systemic therapy, leading to adverse outcomes. Early recognition and management of cardiovascular risk factors before, during, and after cancer treatment are of utmost importance. This review presents advances, challenges, and opportunities for cardiovascular care in contemporary breast cancer treatment.Abstract: Copyright (c) 2018 Elsevier Inc. All rights reserved.